MAJOR FIELDS OF STUDIES
Commissioned studies in the fields of dermatology and medical cosmetics
Years of experience in the field of dermatology as well as extensive study experience have made us a very popular study partner concerning dermatological pharmaceuticals. With Dr. Martina Ulrich as medical director we have internationally recognized competence at our disposal for commissioned dermatological studies. In addition, Collegium Medicum Berlin has all the latest diagnostic procedures and modern technical possibilities for the professional conduct of clinical studies in phases II to IV.
Organizing and conducting studies for doctors and clinics from all disciplines
In addition to clinical trials under their own medical management, we offer specialist physicians either complete service for the planning, implementation and evaluation of clinical trials, including the handling of all administrative and regulatory obligations. Doctors
CLIENTS
Informations for clients
Our clients are usually international and national pharmaceutical companies in the fields of dermatology and medical cosmetics.
Collegium Medicum Berlin offers medical management and complete service for the planning, implementation, evaluation and publication of clinical trials, including the handling of all administrative and regulatory obligations.
During planning, your ideas as the client are naturally taken into account, whereby we as experts examine the execution of the study with regard to quality, efficiency and feasibility.
In addition to the planning and execution of studies, we also aim towards processing data for publication as well as distribution and marketing results.
Subjects
The conduct of clinical trials for the development and improvement of medication ist crucial. The aim of clinical trials, for example, is the development of technical methods for diagnosis, medical cosmentics or mor effective drugs for combating diseases. New drugs for the patient often mean new hope and maybe even healing. Without the cooperation of patients such development and medical advancement is not possible.
We only carry out research projects in which substances have been previously tested in laboratory studies and on healthy volunteers. The aim of clinical studies is therefore to prove the general efficacy of new substances as well as on ill patients. Here, efficacy is usually compared to a socalled placebo.
Our Study Group Collegium Medicum Berlin is located in the heart of Berlin, right next to the Charité Campus Mitte. Access to public transport ist excellent. Kontakt
With us you can become a subject and actively participate as a test person for new and further developments of pre-tested products.
Participation
If you are not yet a participant in a study of Collegium Medicum Berlin but you have interest in study participation you can register your interest via the following email address: mail@collegiummedicum.de
Please contact us on +49 30-278 794 111 with inquiries. (Voicemail, we will call you back)
Please note that eache study requires your presence at least once a tour institute. Your residence should therefore be located in or around Berlin area.
Process
Contact
Please contact our Study Nurse at: mail@collegiummedicum.de
We are happy to also give you information via telephone and will answer your questions.
Participation
If you decide to participate in one of our studies, we will explain you the inclusion and exclusion criteria on the phone as well as time necessary for the study. If nothing stands in the way of participation on both sides we will arrange the first appointment; you will also receive appointment confirmation via email or by post.
Screening visit
At the first appointment all relevant information for the study will be given to you. After you have given informed consent questionnaires as well as skin-specific measurements or tests are performed in order to find out if you are suitable for the study. Here you will receive all your scheduled appointments for the course of the study.
Course of the study
Follow up duration the study will be performed at predetermined intervals to ensure a reliable application of the test product.
Completion
Upon completion date an investigation is again carried out and your health condition is compared with the status at the start of the study. Here, questionnaires for self-reporting or with regard to the test-product may be handed out.
DATA PROTECTION AND PRIVACY POLICY
Information for DSG-VO Read the complete Information
Medical Confidentially
It ist understood that your medical information is treated confidentiality. In order that the study can be evaluated you and your data are subject to special protection. Data protection in Germany is among the best in the world. Our employees are also subject to medical confidentiality.
Anonymity
To ensure that your data obtained in the course of the study cannot be associated with you, you will receive a patient-subject number which bears no relation to your birth date or name. There is only one list, which remains in our hands at all times, on which you are listed with real name, adress, date of birth and study-related number. This list is not available to persons about whom you have not been informed of in advance.
In the consent form for your study, you will always find appropriate information on the purpose and scope of the planned data processing. Of course, we will also gladly answer any of your questions.
Please understand that you cannot participate in a study without consenting to the further processing of your data generated in the course of clinical trials.
DOCTORS
Clinical trials are the core business of Collegium Medicum Berlin GmbH. The focus of our clinical trials are in the fields of dermatology and medical cosmetics.
Clinical Trials
MOB015B-III - A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in treatment of mild to moderate distal subungual onychomycosis UDSO) (Phase III) Moberg Pharma AB, EudraCT-Nr. 2016-001204-39 –
Status: Recruitment finished
ALA-AK-CT010 - A randomized, double-blind, intra-individual, multi-centre phase III study to evaluate the safety and efficacy of BF-200 ALA vs. placebo in the treatment of mild to severe actinic keratosis on extremities, trunk/neck with photodynamic therapie (PDT) when using the BF-RhodoLED lamp Biofrontera Bioscience GmbH, EudraCT-Nr. 2017-000486-72 –
Status: Recruitment finished
Rosacea - A multi-centre, randomized, double-blind, parallel-group, placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules Compared to Placebo for the Treatment of Inflammatory Lesions of Rosacea over 16 Weeks –
QPS, EudraCT-Nr. 2016-003197-41
Status: Recruitment finished
ALA-BCC-CT008 - Efficacy and Safety of LEO 43204 in Field Treatment of Basal Cell Carcinoma on Face or Chest including 12-month follow-up (Phase III, multizentrisch, einarmig, open-label, 8 Wochen Dauer) LEO-Pharma GmbH, EudraCT-Nr. 2013-003241-42 –
Status: Recruitment finished